Recruiting
Phase 2

Triheptanoin

Sponsor:

Center for Rare Neurological Diseases, Norcross, GA

Code:

NCT02696044

Conditions

Rett Syndrome

Eligibility Criteria

Sex: Female

Age: 2+

Healthy Volunteers: Not accepted

Interventions

triheptanoin

Study Details

Brief summary:

The aim of this study is to evaluate the safety and tolerability of triheptanoin in participants with Rett syndrome using laboratory values, electrocardiogram, rate of adverse events (AE), and physical exam.This study also seeks to evaluate the efficacy of UX007 (triheptanoin) in improving overall seizure frequency and dystonia.

Conditions

Rett Syndrome

Study ID

NCT02696044

Start date

Jun, 2016

Status verified date

Jul, 2020

Completion date

Feb, 2022

Anticipated

Primary completion date

Feb, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 2+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of Classic Rett syndrome as defined by the clinical consensus criteria
  • Presence of a MECP2 mutation
  • Post-regression stage of development, defined as greater than 6 months since the last loss of hand use or verbal language
  • Average of at least 4 observable seizures (generalized or partial-onset \[Generalized Tonic-Clonic, Generalized Tonic, Generalized Clonic, Generalized Atonic, Partial/Focal with Secondary Generalization, Myoclonic, Myoclonic Atonic, Myoclonic Tonic, Complex Partial/Focal, and Simple Partial/Focal Motor) in one month prior to the study by caregiver report or presence of dystonia on average at least four times in one month prior to the study in at least one body region rated as at least "mild" by caregiver report
  • Use of at least one anti-seizure medication at screening visit
  • At screening visit, managed on four or fewer concomitant anti-seizure medications that must have been stable in dose at least one month prior to the beginning of screening and anticipated to remain stable in dose through the end of the 8.5 month trial period
  • Legally authorized caregiver must be willing to give written informed consent after the nature of the study has been explained, and prior to any research-related procedures
  • Caregiver and participant must, in the opinion of the investigator, be willing and able to complete all aspects of the study, comply with accurate completion of the seizure and dystonia diaries, and be likely to complete the four month treatment period

Exclusion Criteria:

  • Markedly abnormal metabolic screening laboratory testing (e.g., serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2X the upper limit of normal)
  • Any known hypersensitivity to triheptanoin that, in the judgment of the investigator, places the subject at increased risk for adverse effects
  • Prior use of triheptanoin within 1 month prior to screening
  • Participants or caregivers who are unwilling or unable to discontinue use of a prohibited medication or other substance that may confound study objectives
  • Use of any other investigational product, including drugs or supplements within 1 month prior to Screening, or at any time during the study
  • Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment
  • Has a concurrent disease or condition, or laboratory abnormality that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or introduces additional safety concerns (e.g., diabetes mellitus)
  • Pregnant or nursing women

Study Design

Enrollment

12 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Participants aged 0 months to 3 years

Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.

experimental: Participants aged 4 to 6 years

Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.

experimental: Participants aged 7 to 9 years

Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.

experimental: Participants aged 10 to 14 years

Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.

experimental: Participants aged 15 to 20 years

Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.

experimental: Participants aged 21 years and older

Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.

Interventions

triheptanoin

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Primary outcome measure

  • Change in Clinical Seizure Frequency [ Time Frame: Visit 2, Visit 7 (Up to 4 months) ]
  • Change in Dystonia frequency [ Time Frame: Visit 2, Visit 7 (Up to 4 months) ]

Central Contacts and Locations

Central contacts

Daniel Tarquinio, DO

207-590-6945daniel@rareneuro.com

Jennifer Harris

770-315-2207jennifer@rareneuro.com

Locations

Center for Rare Neurological Diseases

Recruiting

Norcross, Georgia, United States, 30093

Contacts

Daniel C Tarquinio, DO

207-590-6945daniel@rareneuro.com

Alice Bruce

617-984-9091alice@rareneuro.com

Principal Investigator:

Daniel Tarquinio, DO

More Information

Sponsor

Center for Rare Neurological Diseases, Norcross, GA

Last update posted

Jul 17, 2020

Last verified

Jul, 2020

Keywords

  • Gastrointestinal Disorders

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Center for Rare Neurological Diseases, Norcross, GA on 2020-07-17.